Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR® 3.0 Software for Coronary Physiology Assessment in the US
Terumo Health Outcomes (THO) has announced the U.S. availability of Medis QFR 3.0, an FDA-cleared software solution for coronary physiology assessment, through its collaboration with Medis Medical Imaging. The AI-powered software aims to enhance catheterization laboratory efficiency and patient comfort.
The technology has been extensively validated through over 200 peer-reviewed publications, with data from more than 17,000 patients and 20,000 lesions. Notably, QFR received recommendation from the European Society of Cardiology in their 2024 ESC Guidelines. THO will showcase QFR 3.0 at the upcoming SCAI 2025 Scientific Sessions.
This software integrates with THO's ePRISM platform, which provides predictive insights for patient risk assessment and treatment optimization, potentially reducing hospital costs and recovery times.
Terumo Health Outcomes (THO) ha annunciato la disponibilità negli Stati Uniti di Medis QFR 3.0, un software approvato dalla FDA per la valutazione della fisiologia coronarica, grazie alla collaborazione con Medis Medical Imaging. Questo software basato su intelligenza artificiale mira a migliorare l'efficienza dei laboratori di cateterismo e il comfort dei pazienti.
La tecnologia è stata ampiamente validata attraverso oltre 200 pubblicazioni peer-reviewed, con dati provenienti da più di 17.000 pazienti e 20.000 lesioni. In particolare, il QFR ha ricevuto una raccomandazione dalla Società Europea di Cardiologia nelle Linee Guida ESC 2024. THO presenterà QFR 3.0 durante le prossime Sessioni Scientifiche SCAI 2025.
Il software si integra con la piattaforma ePRISM di THO, che offre analisi predittive per la valutazione del rischio del paziente e l’ottimizzazione del trattamento, contribuendo potenzialmente a ridurre i costi ospedalieri e i tempi di recupero.
Terumo Health Outcomes (THO) ha anunciado la disponibilidad en EE. UU. de Medis QFR 3.0, un software aprobado por la FDA para la evaluación de la fisiología coronaria, mediante su colaboración con Medis Medical Imaging. Este software impulsado por IA busca mejorar la eficiencia en los laboratorios de cateterismo y la comodidad del paciente.
La tecnología ha sido ampliamente validada con más de 200 publicaciones revisadas por pares, con datos de más de 17,000 pacientes y 20,000 lesiones. Destaca que QFR recibió recomendación de la Sociedad Europea de Cardiología en las Guías ESC 2024. THO presentará QFR 3.0 en las próximas Sesiones Científicas SCAI 2025.
El software se integra con la plataforma ePRISM de THO, que ofrece perspectivas predictivas para la evaluación del riesgo del paciente y la optimización del tratamiento, lo que podría reducir costos hospitalarios y tiempos de recuperación.
Terumo Health Outcomes (THO)는 Medis Medical Imaging과의 협력을 통해 FDA 승인을 받은 관상동맥 생리 평가 소프트웨어인 Medis QFR 3.0을 미국에서 출시했다고 발표했습니다. 인공지능 기반 소프트웨어로서 카테터실의 효율성과 환자 편의를 향상시키는 것을 목표로 합니다.
이 기술은 17,000명 이상의 환자와 20,000개 이상의 병변 데이터를 포함한 200건 이상의 동료 검토 논문을 통해 광범위하게 검증되었습니다. 특히 QFR는 2024년 유럽심장학회(ESC) 가이드라인에서 권고를 받았습니다. THO는 다가오는 2025년 SCAI 과학 세션에서 QFR 3.0을 선보일 예정입니다.
이 소프트웨어는 환자 위험 평가 및 치료 최적화를 위한 예측 인사이트를 제공하는 THO의 ePRISM 플랫폼과 통합되어 병원 비용과 회복 시간을 줄일 수 있습니다.
Terumo Health Outcomes (THO) a annoncé la disponibilité aux États-Unis de Medis QFR 3.0, une solution logicielle approuvée par la FDA pour l’évaluation de la physiologie coronarienne, grâce à sa collaboration avec Medis Medical Imaging. Ce logiciel alimenté par l’IA vise à améliorer l’efficacité des laboratoires de cathétérisme et le confort des patients.
La technologie a été largement validée à travers plus de 200 publications évaluées par des pairs, avec des données provenant de plus de 17 000 patients et 20 000 lésions. Notamment, le QFR a reçu une recommandation de la Société Européenne de Cardiologie dans les lignes directrices ESC 2024. THO présentera QFR 3.0 lors des prochaines Sessions Scientifiques SCAI 2025.
Ce logiciel s’intègre à la plateforme ePRISM de THO, qui offre des analyses prédictives pour l’évaluation du risque patient et l’optimisation du traitement, contribuant potentiellement à réduire les coûts hospitaliers et les temps de récupération.
Terumo Health Outcomes (THO) hat die Verfügbarkeit von Medis QFR 3.0 in den USA bekannt gegeben, einer von der FDA zugelassenen Softwarelösung zur Beurteilung der koronaren Physiologie, die in Zusammenarbeit mit Medis Medical Imaging entwickelt wurde. Die KI-gestützte Software soll die Effizienz von Katheterlaboren verbessern und den Patientenkomfort erhöhen.
Die Technologie wurde umfassend validiert, mit über 200 begutachteten Veröffentlichungen und Daten von mehr als 17.000 Patienten und 20.000 Läsionen. Bemerkenswert ist, dass QFR in den ESC-Leitlinien 2024 von der Europäischen Gesellschaft für Kardiologie empfohlen wurde. THO wird QFR 3.0 bei den kommenden SCAI 2025 Scientific Sessions präsentieren.
Die Software ist in THOs ePRISM-Plattform integriert, die prädiktive Einblicke für die Risikobewertung von Patienten und die Optimierung der Behandlung bietet, was potenziell Krankenhauskosten und Erholungszeiten reduziert.
- FDA clearance obtained for Medis QFR 3.0 software
- Strong clinical validation with 200+ peer-reviewed publications
- ESC Guidelines recommendation received in 2024
- Integration with existing ePRISM platform enhances product ecosystem
- Potential for reduced hospital costs and recovery times
- None.
– Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort –
"Helping hospitals access proven, innovative tools like QFR 3.0 is an important part of our mission," said Ryan Graver, Senior Divisional Vice President, THO. "This latest advancement from Medis aligns with the goals of many hospitals to enhance cath lab efficiency and support high-quality, patient-centered care. We are proud to be able to offer this cardiology diagnostic software solution to our customers."
THO and Medis will showcase QFR 3.0 during the upcoming SCAI 2025 Scientific Sessions, offering clinicians the opportunity to learn more about the technology and its role in supporting efficient, physiology-guided care in the cath lab.
Medis QFR has been validated through extensive clinical research, including over 200 peer-reviewed publications and data from more than 17,000 patients and 20,000 lesions. In 2024, QFR was recommended by the European Society of Cardiology in their ESC Guidelines, reinforcing its clinical relevance and utility.
"We're excited that
"This partnership reflects our shared commitment to expand hospital access to innovative cardiovascular technologies," said Ghada Farah, President of Terumo Interventional Systems.
THO is a division of TIS, which offers a portfolio of high-quality interventional devices that complement the predictive insights offered by THO's ePRISM platform. While ePRISM assists clinicians in identifying patient risk and optimizing treatment strategies, the advanced tools from TIS support procedural efficiency, contributing to improved patient outcomes. This combination assists clinicians to make more informed decisions, facilitating smoother procedures and potentially reducing hospital costs and recovery times.
About Terumo Health Outcomes
Terumo Health Outcomes (THO) delivers advanced digital health solutions that empower clinicians with predictive insights to optimize patient care and hospital efficiency. The ePRISM platform helps provides personalized patient care, which is provided to the clinician on a screen in real-time as a decision support tool, enabling hospitals to implement data-driven care strategies that enhance patient outcomes and streamline operational performance. Learn more at www.terumohealthoutcomes.com.
About Terumo
Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for over 100 years. Based in
About Medis Medical Imaging
For over 35 years, Medis has been providing innovative, robust, and extensively validated tools to the medical community worldwide. The heritage and core values are based on this strong purpose of contributing to a healthier society by providing the right tools to cardiologists, radiologists, researchers, and industry partners. Medis' software is internationally appreciated due to its ease of use and its clinical outcome for the patients. At Medis, quality is key. All products are developed and validated extensively to guarantee the highest quality, without compromise. They continuously focus on the creation of clinically relevant innovative software solutions in the cardiovascular imaging domain.
View original content to download multimedia:https://www.prnewswire.com/news-releases/terumo-health-outcomes-now-offers-fda-cleared-medis-qfr-3-0-software-for-coronary-physiology-assessment-in-the-us-302430661.html
SOURCE Terumo Health Outcomes
FAQ
What clinical validation does Medis QFR 3.0 software (TRUMY) have?
How will Medis QFR 3.0 benefit hospitals using Terumo (TRUMY) systems?
When will Terumo (TRUMY) showcase the QFR 3.0 software to clinicians?
What regulatory approvals has Terumo's (TRUMY) Medis QFR 3.0 received?
